Search Within

Anthony R Mato

Formats
  1. Meeting Abstract (135)
  2. Journal Article (63)
  3. Review (16)
  4. Research Letter (10)
  5. Editorial (7)
  6. Guidelines (3)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (236)
  2. Center for Hematologic Malignancies (236)
  3. Department of Medicine (236)
  4. Hematologic Malignancies, Division of (236)
  5. Hematology-Oncology Fellows (101)
  6. Lymphoma (47)

More Groups

People
  1. Lindsey Roeker (94)
  2. Andrew Zelenetz (33)
  3. Meghan Thompson (30)
  4. Omar Abdel-Wahab (19)
  5. Maria Palomba (18)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (4)
  2. 2024 (2)
  3. 2023 (22)
  4. 2022 (49)
  5. 2021 (39)
  6. 2020 (52)

More Years

Publications
  1. Blood (82)
  2. Journal of Clinical Oncology (18)
  3. Clinical Lymphoma, Myeloma and Leukemia (16)
  4. Leukemia and Lymphoma (16)
  5. British Journal of Haematology (15)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. American Society of Clinical Oncology (19)
  3. Elsevier Inc. (18)
  4. Taylor & Francis Group (18)
  5. John Wiley & Sons (16)
  6. American Association for Cancer Research (10)

More Publishers

Results (236)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse
    Journal Article

    Hu, R.; Wei, W.; Mian, A.; Gonter-Aubin, K.; Kabel, C.; Mato, A.; Stephens, D. M.; Hanlon, A.; Khajavian, S.; Shadman, M.; more...
    European Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
    Review

    Nocco, S.; Andriano, T. M.; Bose, A.; Chilov, M.; Godwin, K.; Dranitsaris, G.; Wu, S.; Lacouture, M. E.; Roeker, L. E.; Mato, A. R.; more...
    Critical Reviews in Oncology/Hematology (2022)

    Fulltext@MSK | Save
  • Highlights in chronic lymphocytic leukemia from the 63rd American Society of Hematology Annual Meeting and Exposition: Commentary
    Editorial

    Mato, A.
    Clinical Advances in Hematology & Oncology (2022)

    Fulltext@MSK | Save
  • Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors
    Journal Article

    Wang, E.; Mi, X.; Thompson, M. C.; Montoya, S.; Notti, R. Q.; Afaghani, J.; Durham, B. H.; Penson, A.; Witkowski, M. T.; Lu, S. X.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Current treatment of chronic lymphocytic leukemia: The diminishing role of chemoimmunotherapy
    Review

    Roeker, L. E.; Thompson, M.; Mato, A. R.
    Drugs (2022)

    Fulltext@MSK | Save
  • Recognizing unmet need in the era of targeted therapy for CLL/SLL: “What's past Is prologue” (Shakespeare)
    Journal Article

    Mato, A. R.; Davids, M. S.; Sharman, J.; Roeker, L. E.; Kay, N.; Kater, A. P.; Rogers, K.; Thompson, M. C.; Rhodes, J.; Goy, A.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: Post-hoc analyses from the phase III MURANO study
    Journal Article

    Mato, A. R.; Sharman, J. P.; Biondo, J. M. L.; Wu, M.; Mun, Y.; Kim, S. Y.; Humphrey, K.; Boyer, M.; Zhu, Q.; Seymour, J. F.
    Haematologica (2022)

    Fulltext@MSK | Save
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
    Meeting Abstract

    Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Hill, M.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
    Meeting Abstract

    Mato, A. R.; Wierda, W. G.; Pagel, J. M.; Davids, M. S.; Zinzani, P. L.; Lu, Y.; Liu, H.; Shahda, S.; Leow, C. C.; Tam, C. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save